Elham Askari

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Case Report: Central nervous system relapse treated with elranatamab after prior BCMA and GPRC5D directed therapies in relapsed/refractory multiple myeloma.

Case Report: Central nervous system relapse treated with elranatamab after prior BCMA and GPRC5D directed therapies in relapsed/refractory multiple myeloma.

Journal: Frontiers in oncology
Published: May 24, 2026

Development of PREVEMM: A Venous Thromboembolism Risk Score for Newly Diagnosed Multiple Myeloma Patients.

Development of PREVEMM: A Venous Thromboembolism Risk Score for Newly Diagnosed Multiple Myeloma Patients.

Journal: Clinical lymphoma, myeloma & leukemia
Published: July 14, 2025

Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis.

Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis.

Journal: Blood advances
Published: May 20, 2025

Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis.

Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis.

Journal: Blood cancer journal
Published: May 03, 2025

Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain.

Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain.

Journal: Therapeutic advances in hematology
Published: April 02, 2025

Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy.

Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy.

Journal: Journal of thrombosis and thrombolysis
Published: February 13, 2025

Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry.

Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry.

Journal: HemaSphere
Published: April 26, 2024

Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.

Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.

Journal: Future oncology (London, England)
Published: July 26, 2023

Frailty assessment to individualize treatment in older patients with lymphoma.

Frailty assessment to individualize treatment in older patients with lymphoma.

Journal: European geriatric medicine
Published: June 20, 2023

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.

Journal: Cancers
Published: April 20, 2023

Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level.

Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level.

Journal: Disease models & mechanisms
Published: April 04, 2023

Invasive Cutaneous Candidiasis, Autoimmune Hemolytic Anemia and Pancytopenia: A Challenging Scenario for Waldenström Macroglobulinemia in an Elderly Patient.

Invasive Cutaneous Candidiasis, Autoimmune Hemolytic Anemia and Pancytopenia: A Challenging Scenario for Waldenström Macroglobulinemia in an Elderly Patient.

Journal: Biomedicines
Published: January 25, 2023
Showing 1-12 of 25

Last Updated: 09/26/2026